LCTX
AMEX · Biotechnology
Lineage Cell Therapeutics In
$1.03
+0.00 (+0.00%)
Open$1.02
Previous Close$1.03
Day High$1.06
Day Low$1.00
52W High$2.09
52W Low$1.00
Volume—
Avg Volume1.20M
Market Cap260.49M
P/E Ratio—
EPS$-0.14
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+3,824.3% upside
Current
$1.03
$1.03
Target
$40.42
$40.42
$29.91
$40.42 avg
$53.83
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.36M | 8.29M | 231.61M |
| Net Income | -71,210,481 | -39,777,453 | -65,233,876 |
| Profit Margin | -240.2% | -228.2% | -28.2% |
| EBITDA | -40,260,616 | -23,738,570 | -95,106,936 |
| Free Cash Flow | — | — | -33,113,271 |
| Rev Growth | +61.1% | +61.1% | -6.2% |
| Debt/Equity | 0.00 | 0.00 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |